



*Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medicine for more than 50 years, is dedicated to creating and providing pioneering medical imaging solutions to improve the treatment of human disease.*

The company's proven success in discovering, developing and marketing innovative medical imaging agents provides a solid platform from which to advance new tools for the diagnosis and management of disease. Lantheus is home to leading cardiac imaging brands, including **Cardiolite®** (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), **DEFINITY®** Vial For (Perflutren Lipid Microsphere) Injectable Suspension and **TechneLite®** (Technetium Tc99m Generator). The company is also now home to **ABLAVAR™** (gadofosveset trisodium), the first and only blood pool contrast agent approved for magnetic resonance angiography in the United States. Lantheus has nearly 600 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia.

### *A Proud Heritage*

For more than half a century, Lantheus Medical Imaging, Inc. has helped physicians enhance patient care with its pioneering product portfolio that illuminates the heart and other organs. Formed in 1956 as New England Nuclear Corporation (NEN), the company grew to become a leader in the field of diagnostic imaging and later evolved through its transition from NEN to DuPont, and then Bristol-Myers Squibb (BMS) Medical Imaging. In 2008, BMS Medical Imaging was acquired by Avista Capital Partners and formally re-launched as Lantheus Medical Imaging, operating for the first time in its proud history as an independent company.

## RECENT LANTHEUS NEWS

10/08/09

Data Featuring Gadofosveset Trisodium, the First and Only MRA Blood Pool Agent Approved in the U.S., Presented at MRA-Club 09: 21st Annual International Conference on Magnetic Resonance Angiography

09/17/09

Lantheus Medical Imaging, Inc. Initiates Phase 1 Study Evaluating Safety and Dosimetry of Novel Heart Failure Imaging Agent

08/14/09

Lantheus Continues to Address Industry Shortage of Mo-99 Resulting from Prolonged NRU Reactor Shutdown

07/09/09

Lantheus Medical Imaging, Inc. Announces FDA and Health Canada Approval of Australian Nuclear Science and Technology Organisation (ANSTO)-Supplied Key Medical Isotope to Manufacture TechneLite® Generator

06/14/09

Scientists Who Made Significant Contribution to Discovery of Lantheus Medical Imaging's Cardiolite® Honored With Prestigious Nuclear Medicine Award at SNM Annual Meeting

### MANAGEMENT

#### DON KIEPERT

President and CEO

#### LARRY PICKERING

Executive Chairman

#### PETER CARD

Vice President,  
Corporate Development

#### WILLIAM DAWES

Vice President,  
Manufacturing and Supply Chain

#### MICHAEL DUFFY

Vice President,  
General Counsel and Secretary

#### D. SCOTT EDWARDS

Vice President, Global R&D

#### ROBERT GAFFEY

Vice President,  
Finance and Operations; Treasurer

#### PHILIP LOCKWOOD

Vice President, Human Resources

#### DAVID MANN

Vice President,  
Sales and Marketing

#### CYRILLE VILLENEUVE

Vice President and  
General Manager, International

## CONTACTS

### LANTHEUS MEDICAL IMAGING, INC.

Building 200-2  
331 Treble Cove Road  
N. Billerica, MA 01862

### MEDIA CONTACT

PRISCILLA HARLAN  
Senior Director,  
Corporate Communications  
978-671-8854

MICHELE ROZEN  
Pure Communications, Inc.  
617-730-8284



© 2009 Lantheus  
Medical Imaging, Inc.®

## A Compelling Pipeline

Lantheus Medical Imaging, Inc. is committed to investing in the field of nuclear medicine and developing the next generation of diagnostic products to advance patient care. With proven expertise in discovering and developing imaging diagnostics, Lantheus is focused on meeting the need for improved medical imaging tools and building on its strong foundation of pioneering research and development. The company's clinical development efforts include promising programs to develop novel Positron Emission Tomography (PET) imaging tracers, including BMS747158, an F-18 labeled myocardial perfusion imaging agent, now in Phase 2 clinical trials, as well as LMI1195, a unique heart failure imaging agent in Phase 1 clinical trials to evaluate safety and dosimetry. Additionally, Lantheus has early stage programs in the areas of imaging vulnerable plaque and other disease states.

## A Growing Vision

At Lantheus Medical Imaging, Inc., our vision is to be the leading provider of innovative medical imaging solutions to improve human life. Our rich heritage and R&D expertise in nuclear medicine provide a strong foundation on which to grow our vibrant business. With fully integrated research, clinical and commercial operations, the company's growth strategy is firmly focused around three core areas:

- **Maximize** our existing product portfolio through our unparalleled distribution network, superior customer service, outstanding sales and medical affairs field organization, and radiopharmaceutical manufacturing processes
- **Leverage** and utilize our core competencies in sales and marketing, R&D and manufacturing to in-license products that are a strategic fit and will help better manage the patients who will ultimately benefit from our efforts
- **Invest** in key pipeline initiatives we have discovered to create the next generation of diagnostic tools to advance patient care. Lantheus currently invests 8-10% of all revenues in our pipeline, to ensure that our R&D organization has the resources to continue discovering and developing tomorrow's diagnostic tools.

## TIMELINE OF INNOVATION

### 2009

Lantheus Medical Imaging, Inc. acquires U.S., Canadian and Australian rights to gadofosveset trisodium from EPIX Pharmaceuticals. ABLAVAR™ is designated as brand name for gadofosveset trisodium

### 2008

BMS sells its medical imaging division to Avista Capital Partners. Lantheus Medical Imaging, Inc. is launched

### 2001

Bristol-Myers Squibb Co. (BMS) purchases DuPont Pharmaceuticals

### 2001

DEFINITY® is launched in the U.S.

### 1998

DuPont buys Merck's interest, becomes DuPont Pharmaceuticals

### 1995

NEUROLITE® is launched in the U.S.

### 1991

DuPont forms venture with Merck called DuPont Merck

### 1991

Cardiolite® is launched in the U.S.

### 1981

DuPont purchases NEN

### 1977

Thallium is launched

### 1956

New England Nuclear Corporation (NEN) is formed

